Evaluation of multi-target iridium(iii)-based metallodrugs in combating antimicrobial resistance and infections caused by .

The rapid emergence and spread of multidrug-resistant bacteria pose a serious challenge to human life and health, necessitating the development of novel antibacterial agents. Herein, to address this challenge, three iridium-based antibacterial agents were prepared and their antimicrobial activity were explored. Importantly, the three complexes all showed robust potency against with MIC values in the range of 1.9-7.9 μg mL. Notably, the most active complex Ir3 also exhibited relative stability in mammalian fluids and a significant antibacterial effect on clinically isolated drug-resistant bacteria. Mechanism studies further demonstrated that the complex Ir3 can kill by disrupting the integrity of the bacterial membrane and inducing ROS production. This multi-target advantage allows Ir3 to not only effectively combat bacterial resistance but also efficiently clear the bacterial biofilm. In addition, when used together, complex Ir3 could enhance the antibacterial potency of some clinical antibiotics against . Moreover, both wax worms and mouse infection model demonstrated that Ir3 has low toxicity and robust anti-infective efficacy . Overall, complex Ir3 can serve as a new antibacterial agent for combating Gram-positive bacterial infections.